Работы, цитирующие эту работу

Работ: 3

Работа: Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

1. Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology

   Jinxin Dong, Denis Nikolenko, Shuxrat Boymuradov +2

   СтатьяCAR-T cell therapy researchClinical & Translational Oncology2026Цитирований: 1

   ABIABI:AkademIndex/openalex/2026.article.000172

2. Genetic engineering in oncology based on CRISPR-Cas9 technology

   D. Polatova, А. Yu. Madaminov, А. V. Savkin +1

   СтатьяCRISPR and Genetic EngineeringSiberian Journal of Oncology2024Цитирований: 0

   ABIABI:AkademIndex/openalex/2024.article.008036

3. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   СтатьяCAR-T cell therapy researchJournal of Hematology & Oncology2025Цитирований: 0

   ABIABI:AkademIndex/openalex/2025.article.000083